<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN"
"http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" lang="en" xml:lang="en">
<head>
<title></title>
<!-- 2015-03-10 Tue 16:31 -->
<meta  http-equiv="Content-Type" content="text/html;charset=utf-8" />
<meta  name="generator" content="Org-mode" />
<meta  name="author" content="David Mann" />
<style type="text/css">
 <!--/*--><![CDATA[/*><!--*/
  .title  { text-align: center; }
  .todo   { font-family: monospace; color: red; }
  .done   { font-family: monospace; color: green; }
  .priority { font-family: monospace; color: orange; }
  .tag    { background-color: #eee; font-family: monospace;
            padding: 2px; font-size: 80%; font-weight: normal; }
  .timestamp { color: #bebebe; }
  .timestamp-kwd { color: #5f9ea0; }
  .right  { margin-left: auto; margin-right: 0px;  text-align: right; }
  .left   { margin-left: 0px;  margin-right: auto; text-align: left; }
  .center { margin-left: auto; margin-right: auto; text-align: center; }
  .underline { text-decoration: underline; }
  #postamble p, #preamble p { font-size: 90%; margin: .2em; }
  p.verse { margin-left: 3%; }
  pre {
    border: 1px solid #ccc;
    box-shadow: 3px 3px 3px #eee;
    padding: 8pt;
    font-family: monospace;
    overflow: auto;
    margin: 1.2em;
  }
  pre.src {
    position: relative;
    overflow: visible;
    padding-top: 1.2em;
  }
  pre.src:before {
    display: none;
    position: absolute;
    background-color: white;
    top: -10px;
    right: 10px;
    padding: 3px;
    border: 1px solid black;
  }
  pre.src:hover:before { display: inline;}
  pre.src-sh:before    { content: 'sh'; }
  pre.src-bash:before  { content: 'sh'; }
  pre.src-emacs-lisp:before { content: 'Emacs Lisp'; }
  pre.src-R:before     { content: 'R'; }
  pre.src-perl:before  { content: 'Perl'; }
  pre.src-java:before  { content: 'Java'; }
  pre.src-sql:before   { content: 'SQL'; }

  table { border-collapse:collapse; }
  caption.t-above { caption-side: top; }
  caption.t-bottom { caption-side: bottom; }
  td, th { vertical-align:top;  }
  th.right  { text-align: center;  }
  th.left   { text-align: center;   }
  th.center { text-align: center; }
  td.right  { text-align: right;  }
  td.left   { text-align: left;   }
  td.center { text-align: center; }
  dt { font-weight: bold; }
  .footpara:nth-child(2) { display: inline; }
  .footpara { display: block; }
  .footdef  { margin-bottom: 1em; }
  .figure { padding: 1em; }
  .figure p { text-align: center; }
  .inlinetask {
    padding: 10px;
    border: 2px solid gray;
    margin: 10px;
    background: #ffffcc;
  }
  #org-div-home-and-up
   { text-align: right; font-size: 70%; white-space: nowrap; }
  textarea { overflow-x: auto; }
  .linenr { font-size: smaller }
  .code-highlighted { background-color: #ffff00; }
  .org-info-js_info-navigation { border-style: none; }
  #org-info-js_console-label
    { font-size: 10px; font-weight: bold; white-space: nowrap; }
  .org-info-js_search-highlight
    { background-color: #ffff00; color: #000000; font-weight: bold; }
  /*]]>*/-->
</style>
<script type="text/javascript">
/*
@licstart  The following is the entire license notice for the
JavaScript code in this tag.

Copyright (C) 2012-2013 Free Software Foundation, Inc.

The JavaScript code in this tag is free software: you can
redistribute it and/or modify it under the terms of the GNU
General Public License (GNU GPL) as published by the Free Software
Foundation, either version 3 of the License, or (at your option)
any later version.  The code is distributed WITHOUT ANY WARRANTY;
without even the implied warranty of MERCHANTABILITY or FITNESS
FOR A PARTICULAR PURPOSE.  See the GNU GPL for more details.

As additional permission under GNU GPL version 3 section 7, you
may distribute non-source (e.g., minimized or compacted) forms of
that code without the copy of the GNU GPL normally required by
section 4, provided you include this license notice and a URL
through which recipients can access the Corresponding Source.


@licend  The above is the entire license notice
for the JavaScript code in this tag.
*/
<!--/*--><![CDATA[/*><!--*/
 function CodeHighlightOn(elem, id)
 {
   var target = document.getElementById(id);
   if(null != target) {
     elem.cacheClassElem = elem.className;
     elem.cacheClassTarget = target.className;
     target.className = "code-highlighted";
     elem.className   = "code-highlighted";
   }
 }
 function CodeHighlightOff(elem, id)
 {
   var target = document.getElementById(id);
   if(elem.cacheClassElem)
     elem.className = elem.cacheClassElem;
   if(elem.cacheClassTarget)
     target.className = elem.cacheClassTarget;
 }
/*]]>*///-->
</script>
</head>
<body>
<div id="content">
<h1 class="title"></h1>
<div id="outline-container-unnumbered-1" class="outline-2">
<h2 id="unnumbered-1">Dosage and administration</h2>
<div class="outline-text-2" id="text-unnumbered-1">
</div><div id="outline-container-unnumbered-2" class="outline-3">
<h3 id="unnumbered-2">Nonvalvular atrial fibrillation</h3>
<div class="outline-text-3" id="text-unnumbered-2">
<ul class="org-ul">
<li>Recommended dose is 5 mg orally twice daily.</li>
<li>In patients with at least 2 of the following: age ≥80 yrs, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL, recommended dose is 2.5 mg PO BID.</li>
</ul>
</div>
</div>
<div id="outline-container-unnumbered-3" class="outline-3">
<h3 id="unnumbered-3">Prophylaxis of DVT following hip or knee replacement surgery</h3>
<div class="outline-text-3" id="text-unnumbered-3">
<ul class="org-ul">
<li>Recommended dose is 2.5 mg PO BID.</li>
</ul>
</div>
</div>
<div id="outline-container-unnumbered-4" class="outline-3">
<h3 id="unnumbered-4">Treatment of DVT and PE</h3>
<div class="outline-text-3" id="text-unnumbered-4">
<ul class="org-ul">
<li>Recommended dose is 10 mg PO BID for 7 days, then 5 mg PO BID.</li>
</ul>
</div>
</div>
<div id="outline-container-unnumbered-5" class="outline-3">
<h3 id="unnumbered-5">Reduction in the risk of recurrent DVT and PE following initial therapy</h3>
<div class="outline-text-3" id="text-unnumbered-5">
<ul class="org-ul">
<li>Recommended dose is 2.5 mg PO BID.</li>
</ul>
</div>
</div>
</div>
<div id="outline-container-unnumbered-6" class="outline-2">
<h2 id="unnumbered-6">Dosage forms and strengths</h2>
<div class="outline-text-2" id="text-unnumbered-6">
<ul class="org-ul">
<li>Tablets
<ul class="org-ul">
<li>2.5 mg</li>
<li>5 mg</li>
</ul></li>
</ul>
</div>
</div>
<div id="outline-container-unnumbered-7" class="outline-2">
<h2 id="unnumbered-7">Contraindications</h2>
<div class="outline-text-2" id="text-unnumbered-7">
<ul class="org-ul">
<li>Active pathological bleeding</li>
<li>Severe hypersensitivity to apixaban</li>
</ul>
</div>
</div>
<div id="outline-container-unnumbered-8" class="outline-2">
<h2 id="unnumbered-8">Warnings and precautions</h2>
<div class="outline-text-2" id="text-unnumbered-8">
<ul class="org-ul">
<li>Bleeding: serious and potentially fatal bleeding.  Promptly evaluate signs and symptoms of blood loss.</li>
<li>Prosthetic heart valves: Use is not recommended.</li>
</ul>
</div>
</div>
<div id="outline-container-unnumbered-9" class="outline-2">
<h2 id="unnumbered-9">Adverse reactions</h2>
<div class="outline-text-2" id="text-unnumbered-9">
<ul class="org-ul">
<li>Most common adverse reactions (&gt;1%) are related to bleeding</li>
</ul>
</div>
</div>
<div id="outline-container-unnumbered-10" class="outline-2">
<h2 id="unnumbered-10">Drug interactions</h2>
<div class="outline-text-2" id="text-unnumbered-10">
<ul class="org-ul">
<li>For patients receiving apixaban at doses greater than 2.5 mg BID, the dose should be reduced 50% when it is coadministered with strong dual inhibitors of CYP3A4 and P-gp (e.g. ketoconazole, itraconazole, ritonavir, and clarithromycin).  For patients on apixaban 2.5 mg BID avoid coadministration with these drugs.</li>
<li>Simultaneous use of strong dual inducers of CYP3A4 and P-gp (e.g. rifampin, carbamazepine, phenytoin, and St. John's wort) reduces blood levels of apixaban: avoid concomitant use.</li>
<li>Simultaneous use with other anti-platelet or anti-coagualant drugs increases risk of bleeding.</li>
</ul>
</div>
</div>
<div id="outline-container-unnumbered-11" class="outline-2">
<h2 id="unnumbered-11">Use in specific populations</h2>
<div class="outline-text-2" id="text-unnumbered-11">
<ul class="org-ul">
<li>Pregnancy: Not recommended.</li>
<li>Nursing mothers: Discontinue drug or discontinue nursing.</li>
<li>Moderate or severe hepatic impairment: Not recommended.</li>
<li>End stage renal disease on hemodialysis: No change in dosing recommendations, but use caution, as this specific patient population was not included in clinical trials.</li>
</ul>
</div>
</div>
</div>
</body>
</html>
